2017

INTERIM REPORT

天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 8189)

INTERIM REPORT 2017 1

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM")OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors. Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

The information set out in this report, for which the directors of Tianjin TEDA Biomedical Engineering Company Limited ("the Company") collectively and individually accept full responsibility, is given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange for the purpose of giving data with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make this report or any statement herein misleading.

2 TIANJIN TEDA BIOMEDICAL ENGINEERING COMPANY LIMITED

HIGHLIGHTS

  • Consolidated turnover of the Group for the six months ended 30 June 2017 amounted to RMB157,551,363, representing a decrease of 24.77% as compared to the same period of last year (30 June 2016: RMB209,435,809).

  • Consolidated gross profit of the Group for the six months ended 30 June 2017 amounted to RMB21,873,195, representing a decrease of 48.74% as compared to the same period of last year (30 June 2016: RMB42,674,864).

  • Loss attributable to the equity owners of the Company for the six months ended 30 June 2017 was RMB5,805,526, the company's equity owners should make a profit of 8,740,566 in the same period last year; the loss per share of the Company was RMB0.358 cents as compared to earnings per share of RMB0.548 cents of the same period of last year.

  • The Board does not recommend the payment of dividend for the six months ended 30 June 2017.

INTERIM REPORT 2017 3‌

HALF-YEARLY RESULTS (UNAUDITED)

The board of directors (the "Board") of Tianjin TEDA Biomedical Engineering Company Limited (the"Company") is pleased to announce the unaudited half-yearly results of the Company and its subsidiaries (hereafter collectively referred to as the "Group") for the six months ended 30 June 2017, together with the comparative figures of the corresponding period in 2016 as follows:

CONDENSED CONSOLIDATED PROFIT AND LOSS ACCOUNT

(Unaudited)

(Unaudited)

For the six months

ended 30 June

For the three months

ended 30 June

2017

2016

2017

2016

Notes

RMB

RMB

RMB

RMB

Continuing operation

157,551,363

209,435,809

90,376,770

121,018,846

Revenue

2

Cost of sales

(135,678,168)

(166,760,945)

(77,816,419)

(96,118,965)

Gross profit

21,873,195

42,674,864

12,560,351

24,899,881

Other expenses and net loss/Income

(182,077)

(3,162,341)

216,746

(832,598)

Selling and distribution costs

(6,461,881)

(8,564,906)

(3,272,160)

(4,065,144)

R&D and administrative expenses

(18,445,059)

(18,961,631)

(10,450,925)

(10,797,835)

Finance costs

3

(1,812,667)

(1,784,017)

(983,491)

(825,337)

(Loss)/Profit before taxation

(5,028,489)

10,201,969

(1,929,479)

8,378,967

Income tax

5

(691,200)

(1,620,370)

(351,662)

(1,266,086)

(Loss)/Profit and comprehensive income for the period from continuing operation

(5,719,689)

8,581,599

(2,281,141)

7,112,881

Discontinued operation

-

-

-

-

Loss for the period from discontinued operation

(Loss)/Profit and comprehensive income for the period

(5,719,689)

8,581,599

(2,281,141)

7,112,881

Tianjin TEDA Biomedical Engineering Co. Ltd. published this content on 14 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 14 August 2017 02:16:02 UTC.

Original documenthttp://www.bioteda.com/bioteda/pdf/GLN20170814011.pdf

Public permalinkhttp://www.publicnow.com/view/8DC8554A4A615B82B9C85B3761602DC5C3A1E704